| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 78.69B | 79.09B | 78.61B | 82.92B | 75.95B | 73.62B |
| Gross Profit | 15.01B | 14.19B | 14.18B | 14.85B | 15.66B | 16.00B |
| EBITDA | 4.12B | 3.81B | -1.21B | 2.13B | 5.42B | 7.29B |
| Net Income | 712.00M | 427.00M | -8.21B | -1.20B | 1.52B | 3.21B |
Balance Sheet | ||||||
| Total Assets | 78.25B | 79.50B | 82.66B | 86.22B | 80.12B | 76.86B |
| Cash, Cash Equivalents and Short-Term Investments | 6.98B | 7.72B | 6.85B | 6.89B | 7.59B | 8.13B |
| Total Debt | 14.65B | 14.65B | 14.65B | 11.10B | 5.20B | 5.20B |
| Total Liabilities | 39.52B | 40.17B | 43.11B | 40.02B | 32.40B | 30.48B |
| Stockholders Equity | 38.73B | 39.34B | 39.55B | 46.20B | 47.73B | 46.38B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.11B | -2.37B | -5.91B | -1.41B | -733.00M |
| Operating Cash Flow | 0.00 | 2.69B | 1.88B | -1.07B | 4.71B | 4.51B |
| Investing Cash Flow | 0.00 | -1.92B | -3.79B | -4.48B | -5.03B | -2.83B |
| Financing Cash Flow | 0.00 | -1.25B | 1.76B | 4.55B | -860.00M | -650.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥43.82B | 8.53 | ― | 3.53% | -3.45% | 30.52% | |
72 Outperform | ¥10.59B | 15.77 | ― | 2.97% | 9.92% | -27.64% | |
71 Outperform | ¥36.22B | 18.64 | ― | 3.45% | 4.17% | 23.25% | |
65 Neutral | ¥91.59B | 35.93 | ― | 0.67% | 10.18% | -14.36% | |
64 Neutral | ¥29.59B | 97.25 | ― | 4.09% | 3.31% | -70.30% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
53 Neutral | ¥25.83B | -45.30 | ― | 1.39% | -0.12% | ― |
Achilles Corporation has approved the conclusion of a ¥5.4 billion syndicated monetary loan agreement with financial covenants, arranged by Mizuho Bank with MUFG Bank and other lenders, to secure long-term working capital and refinance existing loans. The unsecured facility, scheduled to be signed on February 18, 2026 and maturing in February 2029, includes covenants requiring the company to maintain at least 75% of prior-year net assets and avoid ordinary losses for two consecutive years, measures that signal a focus on financial discipline while the company expects no material impact on its current fiscal-year results.
By locking in longer-term funding under clearly defined balance sheet and earnings conditions, Achilles strengthens visibility over its liquidity position and reassures lenders about its commitment to maintaining capital adequacy and profitability. These terms may enhance the company’s financial stability and credit profile in the medium term, while giving management flexibility to support operations and refinance debt without immediately affecting reported performance for the year ending March 31, 2026.
The most recent analyst rating on (JP:5142) stock is a Buy with a Yen1679.00 price target. To see the full list of analyst forecasts on Achilles Corporation stock, see the JP:5142 Stock Forecast page.
Achilles Corporation has released supplementary materials related to its financial performance for the nine months ended December 31, 2025, and outlined its agenda for investors. The documents indicate that the company will present third-quarter financial results and provide financial forecasts for the fiscal year ending March 31, 2026, signaling continued disclosure to support shareholder and market transparency.
The most recent analyst rating on (JP:5142) stock is a Buy with a Yen1679.00 price target. To see the full list of analyst forecasts on Achilles Corporation stock, see the JP:5142 Stock Forecast page.
Achilles Corporation has revised upward its full-year consolidated and non-consolidated forecasts for operating and ordinary profit for the year ending March 31, 2026, while keeping net sales and bottom-line profit projections unchanged. Profit growth is being driven by strong demand for films in the life sciences sector and industrial materials linked to semiconductor markets, despite ongoing pressures from raw material and energy costs, U.S. tariff policies and volatile exchange rates.
At the same time, the company booked an impairment loss of 905 million yen on fixed assets in its Disaster Response business, recognizing this as an extraordinary loss in results for the nine months to December 31, 2025. This write-down offsets the improved operating performance and explains why the forecast for profit attributable to owners of the parent remains unchanged, highlighting both growth in core businesses and structural challenges in the Disaster Response segment.
The most recent analyst rating on (JP:5142) stock is a Buy with a Yen1679.00 price target. To see the full list of analyst forecasts on Achilles Corporation stock, see the JP:5142 Stock Forecast page.
Achilles Corporation reported consolidated net sales of ¥60.45 billion for the nine months ended Dec. 31, 2025, up 3.4% year on year, with operating profit jumping to ¥2.42 billion and ordinary profit surging more than fivefold. Profit attributable to owners of parent fell 36.8% to ¥1.66 billion, while the equity-to-asset ratio remained solid at 49.8% and net assets per share rose to ¥2,931.09.
The company maintained a stable financial base, with total assets of ¥80.39 billion and no significant changes in its consolidation scope or accounting policies. For the full fiscal year ending March 31, 2026, Achilles forecasts modest sales growth to ¥81.0 billion and a sharp rebound in profit attributable to owners of parent to ¥1.45 billion, and it plans to raise the annual dividend to ¥30 per share, signaling confidence in future earnings and shareholder returns.
The most recent analyst rating on (JP:5142) stock is a Buy with a Yen1679.00 price target. To see the full list of analyst forecasts on Achilles Corporation stock, see the JP:5142 Stock Forecast page.